You are here

Aquavan Trial Meets Primary Endpoint, But a Lower Dose Is More Appropriate for Procedural Sedation

BALTIMORE, March 24 /PRNewswire-FirstCall/ -- Guilford Pharmaceuticals Inc. (NASDAQ:GLFD) today announced that a Phase III study of AQUAVAN(R) Injection in patients undergoing elective colonoscopy procedures met its primary efficacy endpoint without any serious adverse events. The results were based on a randomized, open-label study designed to assess the efficacy of AQUAVAN(R) and its safety versus midazolam HCl for sedation in patients undergoing colonoscopy procedures. A total of 278 patients were enrolled and randomly assigned to receive AQUAVAN(R) (N=209) or midazolam (N=69).

The primary efficacy endpoint in the trial was success of sedation, defined as three consecutive Modified Observer's Assessment of Alertness/Sedation (MOAA/S) scores less than or equal to 4, and completing the procedure without employing alternative sedative medications and without requiring manual or mechanical ventilation. Treatment with AQUAVAN(R) resulted in a sedation success rate of 96%. In general, patients who received AQUAVAN(R) experienced deeper levels of sedation for longer sustained periods than patients who received midazolam, which led to a higher level of adverse events in the AQUAVAN(R) treatment group. Patients treated with AQUAVAN(R) showed a median time to sedation of 2 minutes and a median time to full recovery from the end of the procedure of 11 minutes.

Dean J. Mitchell, President and Chief Executive Officer of Guilford, remarked, "Market research supports the need for a new procedural sedation agent that provides rapid onset and recovery from sedation, is easy to administer and control, and can be safely administered without the need for a dedicated anesthesiologist. Based on these results, we believe AQUAVAN(R) can satisfy that product profile; however, a lower dose than used in this Phase III trial would be more appropriate to meet the characteristics of a drug ideal for procedural sedation. Our intention is to ensure the highest probability of regulatory and commercial success for AQUAVAN(R). Accordingly, we have voluntarily suspended enrolling patients in our ongoing clinical trials in order to review dosing levels. With the dosing level data, in addition to the colonoscopy data, we plan to meet with the Food and Drug Administration within the next several weeks to determine the optimal clinical plan to obtain approval and achieve our desired label. While these activities may modestly extend our timeline for filing the NDA, we think it will best enhance the product's commercial opportunity."

About AQUAVAN(R) Injection
AQUAVAN(R) Injection is a proprietary water-soluble prodrug of propofol. Unlike propofol, which is formulated in an oil or lipid-based emulsion, AQUAVAN(R) is formulated in a clear aqueous solution and is rapidly converted by an enzyme in the body called alkaline phosphatase into propofol after intravenous injection.

Source: Guilford Pharmaceuticals Inc.

Recent Headlines

Scenesse is new treatment for people with rare, painful light sensitivity disease
Humira, Rituxan top list of drugs that added $5.1 billion to nation's health care bill
Lower court rulings cleared the way for generic versions of the MS drug
Maryland man wins lawsuit that alleges that the company's antipsychotic caused his gynecomastia
Antidepressants, ADHD meds are also used to self-poison
Study lists steps that could save close to $300 billion a year
While many victims used THC, the cause remains elusive
Descovy joins Truvada, another Gilead product, in the HIV prophylaxis market
Data show PTC Therapeutics drug preserves lung function